A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 23, 2022

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions

Myelodysplastic SyndromesMyeloproliferative Chronic Myelomonocytic Leukemia

Interventions

DRUG

Cladribine

Given by Vein (IV)

DRUG

Cytarabine

Given under the skin; subcutaneous injection (SQ)

DRUG

Venetoclax

Given by PO

DRUG

Azacitidine

Given by IV or subcutaneous injection (SQ)

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER